|
L-Tryptophanamide
|
DB04537 |
|
|
99mTc-14 F7 Mab
|
DB05867 |
[99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo. Growth inhibition and prolonged survival of the myeloma tumor were obtained as evidences of anti tumor effect after treatment with 99mTc 14F7 Mab. ] |
|
ETC-1001
|
DB05866 |
[ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.] |
|
5-Nitroindazole
|
DB04534 |
|
|
Sphingosine
|
DB03203 |
[An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed)] |
|
5-(Aminomethyl)-2-Methylpyrimidin-4-Amine
|
DB03204 |
|
|
VIT-100
|
DB05865 |
[VIT-100 was developed by ItherX Pharmaceuticals of San Diego. In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control. It is believed that similar effects would be seen in cells isolated from hypertrophic scars.] |
|
PPI-2458
|
DB05864 |
[PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets. PPI-2458 is a novel, proprietary molecule belonging to the fumagillin class of compounds that specifically targets the MetAP-2 enzyme. This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases such as cancer and rheumatoid arthritis. Clinical development with previous fumagillin derivatives has been limited by their toxicity profile. In preclinical studies to date, PPI-2458 has demonstrated the potent pharmacologic activity of this class of compounds while displaying an improved pharmacokinetic and toxicity profile.] |
|
Indole
|
DB04532 |
|
|
D-Cysteine
|
DB03201 |
[A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.] |
|
2-[5-Methanesulfonylamino-2-(4-Aminophenyl)-6-Oxo-1,6-Dihydro-1-Pyrimidinyl]-N-(3,3,3-Trifluoro-1-Isopropyl-2-Oxopropyl)Acetamide
|
DB03202 |
|
|
2-Amino-P-Cresol
|
DB04533 |
|
|
TRX1
|
DB05863 |
[TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.] |
|
S,S-(2-Hydroxyethyl)Thiocysteine
|
DB04530 |
|
|
7-Alpha-D-Ribofuranosyl-Purine-5'-Phosphate
|
DB03200 |
|
|
Benzylcysteine
|
DB04531 |
|
|
Tasquinimod
|
DB05861 |
[The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts] |
|
UC-781
|
DB05871 |
[UC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.] |
|
anti-alpha5Beta1-integrin antibody
|
DB05870 |
[Integrins are important adhesion molecules that regulate tumor and endothelial cell survival, proliferation and migration. The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), as well as other pro-angiogenic growth factors.] |
|
Cholesterol
|
DB04540 |
[The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.] |
